Last reviewed · How we verify

Benzalkonium Chloride-Benzocaine Topical

Medice Arzneimittel Pütter GmbH & Co KG · FDA-approved active Small molecule

Benzalkonium chloride acts as an antimicrobial agent while benzocaine provides local anesthetic effects through sodium channel blockade.

Benzalkonium chloride acts as an antimicrobial agent while benzocaine provides local anesthetic effects through sodium channel blockade. Used for Minor cuts, wounds, and abrasions requiring antiseptic and anesthetic treatment, Topical pain relief with antimicrobial protection.

At a glance

Generic nameBenzalkonium Chloride-Benzocaine Topical
Also known astriple combination
SponsorMedice Arzneimittel Pütter GmbH & Co KG
Drug classTopical antimicrobial-anesthetic combination
TargetBacterial cell membranes (benzalkonium); sodium channels (benzocaine)
ModalitySmall molecule
Therapeutic areaDermatology / Topical antisepsis
PhaseFDA-approved

Mechanism of action

Benzalkonium chloride is a quaternary ammonium compound that disrupts bacterial cell membranes, providing antiseptic/antimicrobial activity. Benzocaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing pain signal transmission. Together, this combination provides both antimicrobial protection and topical pain relief.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: